La Monica, S., Minari, R., Cretella, D., Flammini, L., Fumarola, C., Bonelli, M., . . . Alfieri, R. (2019). Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC. J Exp Clin Cancer Res.
Citação norma ChicagoLa Monica, Silvia, et al. "Third Generation EGFR Inhibitor Osimertinib Combined With Pemetrexed or Cisplatin Exerts Long-lasting Anti-tumor Effect in EGFR-mutated Pre-clinical Models of NSCLC." J Exp Clin Cancer Res 2019.
Citação norma MLALa Monica, Silvia, et al. "Third Generation EGFR Inhibitor Osimertinib Combined With Pemetrexed or Cisplatin Exerts Long-lasting Anti-tumor Effect in EGFR-mutated Pre-clinical Models of NSCLC." J Exp Clin Cancer Res 2019.